The US compassionate experience with thymoglobulin for the treatment of resistant acute rejection

Reduced dose Thymoglobulin®, tacrolimus, and mofetil mycophenolate results in excellent solitary pancreas transplantation outcomes

“…Thymoglobulin ® was originally introduced as treatment for acute rejection of renal allografts. It consists of antibodies against a variety of T cell subsets including CD2, CD3, CD4, CD8, CD11a, CD18, CD25, HLA‐DR, and HLA class I (11). In the renal transplant setting, TMG has been shown to be superior to ATGAM ® in terms of reversing biopsy proven acute rejection (10) in a randomized double‐blinded study.…”